Top 50 Medical Startup Investors in Finland in January 2026

Finnvera makes direct investments in early-stage enterprises through Seed Fund Vera Ltd. Finnvera's goal is to cover shortcomings existing on the market between product development funding and private equity investments. Finnvera does not compete with private financiers; instead, it strives to supplement the financial market.Finnvera'sinvestments enable, start and accelerate growth and internationalisation among investment targets. Enterprises are developed to make them attractive targets for further financing by other investors and industrial actors. Investments are made in technology enterprises at an early stage and in technology-intensive or innovative service enterprises that have potential for developing into international growth enterprises.Finnvera is also known as a specialised financing company owned by the State of Finland. It provides its clients with loans, guarantees, venture capital investments and export credit guarantees.

Business Finland finances business R&D projects and public research projects at universities, research institutes and universities of applied sciences. Read more about R&D and business funding.

Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.

Lifeline Ventures Oy is a venture capital firm specializing in startups, growth capital, and early stage investments. The firm seeks to invest in healthcare, games, web based and general high technology sectors. It seeks to invest in Finland with a few investments made outside Finland as well. The firm targets investing between €0.5 million ($0.66million) and €1 million ($1.32 million). It seeks make inception to Series A investments. Lifeline Ventures Oy was founded in November 2009 and is based in Helsinki, Finland.

Maki.vc is an early-stage venture capital firm partnering with deep tech & brand-driven startups obsessed with challenging category norms.

Butterfly Ventures is a seed-stage focused VC in the Nordics, investing in deep tech, hardware, and hardware interfacing software. The company prefers to get involved with companies early on; 80% of Butterfly Ventures portfolio companies don't have any revenue at the time of their entry. Butterfly Ventures was founded in 2012 and ever sincethen it has been one of the most active early stage VCs in the region. The company has offices in Oulu, Helsinki and Stockholm.

Reaktor Ventures has moved to the next phase by focusing its efforts to actively supporting current portfolio companies. This means that the fund has ended its investment period and is not investing into new companies. Between 2013 and 2018 we have invested into 42 different companies and one early stage fund. We will naturally keep makingfollow-up investments to current portfolio companies.

Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.

Founded in 2016, Icebreaker has invested in over 50 fast-growing tech startups built by domain expert founders from companies like Rovio, Nordea, Pipedrive, Eniram, IBM and BCG. In addition to the fund, Icebreaker also runs a community of more than 1000 founders and pre-founders with 5+ years of relevant industry experience and the will to start,build or join strong tech companies.With the initial ticket sizes of €150k - 800K Icebreaker provides enough funding for companies to get to a position of strength and avoid post-accelerator limbo without having to resort to disreputable sources of capital and unfriendly deal terms.

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

The Citizenship Fund started out when the founders of the company discovered in their previous positions that a promising Finnish growth company will spend a great deal of time and energy in arranging financing. A good business idea and a team with excellent team could take months in financial negotiations and the outcome could be a return to thestart-up. At the same time, investors often wanted new types of higher potential investments alongside traditional alternatives.These two challenges were possible by removing the promising growth companies as investors, even for non-traditional venture capital investors. Citizenship wanted to create a service in which the company would be able to capitalize on business quickly and flexibly, but the decision-making business would be left to the company itself. From today's point of view, Springvest's goal is that an increasing number of Finnish investors can get involved in the story of Finnish growth companies and potential success.

Samsung Venture Investment is plays the role of driving the discovery and development of new businesses and technologies.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

Jyri Engeström is an Investor and Partner of Yes VC. He attended Lancaster University

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Metsola Ventures

As Executive Vice President and General Manager of Multimedia, Nokia, Anssi Vanjoki heads a business group that is responsible for developing Nokia Nseries multimedia computers and associated experiences and services. This fast growing segment of consumer electronics will shape our lives in a fundamental way. A highly respected brand authoritywith over 25 years of marketing experience, Anssi has been a driving force in Nokia's efforts to address the mobile markets. His work has focused on developing Nokia's brand durability, loyalty and continuity, while, at the same time, advancing Nokia's vision of a mobile world. Anssi joined Nokia in 1991 and was named Vice President, Sales, Nokia Mobile Phones, before his promotion in 1994 to Senior Vice President, Nokia Mobile Phones Europe and Africa. In 1998 he was made Executive Vice President, Nokia Mobile Phones Europe and Africa and became a member of the Group Executive Board of Nokia. In addition, in 1999, Anssi took responsibility for Nokia's Digital Convergence Unit and, in 2002, also headed up the Business Unit Management. He was appointed to his present position on January 1st 2004. Prior to joining Nokia, Anssi held a variety of management positions at 3M Corporation. Anssi is the Chairman of the Board of Amer Group, and was a member of the Governing Committee of the European Foundation for Quality Management 2001 - 2003. He is a Knight, 1st Class, of the Order of the White Rose of Finland. Anssi holds a master's degree in economics from the Helsinki School of Economics and Business Administration.

Finnish Industry Investment Ltd is a government-owned investment company. It invests the proceeds accrued from the privatisation of state-owned companies in stimulating the growth and internationalisation of Finnish businesses.Finnish Industry Investment invests in venture capital funds and directly in growth companies, together with privateco-investors. The targets are in all sectors. Capital investments are needed for financing the growth of investee companies, and for spin-offs, major industrial investments, and sector and corporate restructurings.The investments of Finnish Industry Investment amount to over MEUR 570

Inveni Capital is a venture capital management company focused on investments in early to growth stage life sciences companies.

Unifund Jyväskylä Ltd is to support the start-up of research-based businesses.

Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital todate. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.

an early-stage investment firm making long-term bets on contrarians and leveraging the knowledge and network across sectors. We back mission-driven founders working on positively disruptive deep technologies.

Marten Mickos is the CEO of HackerOne, Inc. the leading vulnerability coordination and bug bounty platform. Previously Marten was the CEO of Eucalyptus Systems, acquired by Hewlett-Packard where he served as head of the cloud business. As the CEO of MySQL AB from 2001 to 2008, Marten grew that company from a garage start-up to the second largestopen source company in the world. Marten holds a M.Sc. in technical physics from Helsinki University of Technology in his native Finland.

Asko Schrey

MVM invests in innovative healthcare companies. Our active portfolio companies are transforming the delivery of healthcare by enabling higher quality, cost-effective care in large, global markets.

96 Normal 0 false false false EN-GB X-NONE X-NONE

We partner with founders to transform unseen scientific discoveries into future breakthroughs, jointly moving businesses, people, and the world forward.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds

Jukka Tapaninen is an experienced IT business executive and a board member at Fimmic. Jukka also holds board positions at weVision, Addoro Ab, Findity and MeshWorks Wireless Oy.Jukka has a strong background in the IT industry on managing companies and business units globally. His leadership experience, from large companies like SAP and HP, aswell as from strong midsize companies has given him industry knowledge and excellent network within the strategic ecosystem and major customers. Jukka has experience in working in the United States, Singapore and multiple locations in Europe that have given him a good understanding on how business is done in different parts of the world.Jukka holds a M.Sc. degree from the Helsinki School of Economics.

Wellville is a 10-year national nonprofit project to achieve equitable wellbeing. We support the efforts of The Wellville 5: Five US communities.

Healthcare business development, management, and investing. Very good knowledge on healthcare services and public health. Kustaa Piha is interested in new business and investment opportunities and better ways of producing excellent healthcare services.

Athensmed Oy

cross-border, healthcare, life science, investment, VC, China, US

We are the home for entrepreneurs with a big vision who want to create something less ordinary. Something that matters. For all of us.

Esther Dyson - Founder @ Way to Wellville

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

At DigiTx Partners,we believe that the pace of change in healthcare will only accelerate in the coming years. We believe that there are many smart people with great insights and drive who are developing innovative technologies and solutions. We look forward to supporting innovative companies that will make a difference in our healthcareecosystem, from companies that will change how patients navigate the healthcare system, that will integrate the disparate elements that comprise both diagnosis and treatment, that will speed the development of more effective drugs and that will enhance and enable efficient and accurate physician-patient interaction. DigiTx Partners looks forward to investing in those digital health companies that strive to keep all of us in better health.

Debiopharm invests in Smart Data & Digital Health companies developing technologies that are applicable in the areas of oncology or infectious diseases

Cor Group management consulting firm serving Psychological, Educational, and Behavioral Services.

Torrey Pines Investment, founded in 2002, is a specialty life-science investment company located in San Diego.Torrey Pines has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has created biopharma incubators investing in early development stage assets from internationalpharma and biotech partners in CNS, oncology, and virology areas to bring them to commercial success through pharma partnering and M&A.We are committed to capitalizing on the unique opportunities in biotech and pharma, where we can add value in development or regulatory strategy by utilizing resources of our portfolio CRO companies. We seek to leverage our industry knowledge, network of industry and financial contacts, and internal resources to assist our portfolio management in developing and executing their business strategy. Our bottom line is to help our companies achieve growth, build value and realize wealth.

J12 is a thesis-driven venture capital firm partnering early with technical founders across Europe to build category-defining data and AI companies across infrastructure, tooling, and domain-specific applications

Ali Omar is a Member of the Finnish Business Angels Network. He attended Aalto University and the University of Oulu.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Korpun Siemen is backed by 33 investors who have combined their initial investment activities and have extensive experience in start-up, growth and family businesses in various industries. The company includes active angel investors, entrepreneurs in growth companies and investors who have already exited their companies.

XR Invest is an investment firm focused on medtech and digital health early-stage start-ups.

Petri Pöyhönen

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

WE HELP YOU TO GROW FASTER!